ERBB2 and breast carcinoma: In ER+ breast cancer cells with an aromatase inhibitor resistant phenotype, MYC expression is upregulated by the cross-talk between ER and HER2 and Faslodex inhibited MYC, glutamine transporter solute carrier family (SLC) 1A5, glutaminase (GLS), and glutamine consumption [23].